Below are the financial statements of WuXi Biologics (Cayman), including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in billions of CNY | 2024 | 2023 |
|---|---|---|
| Revenue | 18.68a | 17.03a |
| Cost of sales | -11.02a | -10.21a |
| Gross profit | 7.65a | 6.83a |
| Other income | 0.59a | 0.42a |
| Impairment losses under expected credit loss model, net of reversal | -0.15a | -0.32a |
| Other gains and losses | -0.18a | 0.04a |
| Selling and marketing expenses | -0.47a | -0.29a |
| Administrative expenses | -1.67a | -1.5a |
| Research and development expenses | -0.77a | -0.79a |
| Other expenses | 0a | -0.05a |
| Financing costs | -0.16a | -0.16a |
| Profit before tax | 4.83a | 4.17a |
| Income tax expense | -0.89a | -0.6a |
| Profit for the year | 3.95a | 3.57a |
| Profit for the year attributable to | — | — |
| Owners of the company | 3.36a | 3.4a |
| Non-controlling interests | 0.59a | 0.17a |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore WuXi Biologics (Cayman)’s data sources below and access millions more through our Disclosure Search.
Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.